MXC

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Mgc Pharmaceuticals Ltd

🇦🇺 ASX

📦 LOGISTICS

👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

+ 220.00%
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

7
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

📈 Performance

Price History

+1900.00%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.42

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in MXC

0

📊 Total Capital Earnings

$3K

🔃 Average investment frequency

37 weeks

💵 Average investment amount

$435

Last time a customer invested in MXC

552 days
MXC investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in MXC also invest in...

Argent Biopharma Limited

RGT

Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.

🙌 Performance (5Yr p.a)

128.57%

📊 Share price

$0.26 AUD

📦 LOGISTICS

Find Out More

MGC Pharmaceuticals Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

📊 Share price

$0.42 AUD

NULL STOCK

IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.

🙌 Performance (5Yr p.a)

2.67%

📊 Share price

$4.92 AUD

💸 FINANCIALS

FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

🙌 Performance (5Yr p.a)

2.63%

📊 Share price

$20.56 AUD

🇦🇺 AUSTRALIA

💸 FINANCIALS

⛳️ DIVERSIFIED

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

🙌 Performance (5Yr p.a)

9.42%

📊 Share price

$35.13 AUD

🩺 HEALTH CARE

🇦🇺 EX AUSTRALIA

🤖 TECHNOLOGY

📈 HIGH PRICE GROWTH